Mag­ic mush­rooms treat de­pres­sion, anx­i­ety felt by can­cer pa­tients; Mer­ck wins a speedy re­view sched­ule for lat­est Keytru­da ini­tia­tive

Yes­ter­day’s sto­ry about the po­ten­tial use of an il­lic­it drug for a neu­ropsy­chi­atric con­di­tion fo­cused on MD­MA (ec­sta­sy) for post-trau­mat­ic stress dis­or­der. To­day we got word of two small stud­ies that ex­plored the pow­er­ful im­pact of psilo­cy­bin (mag­ic mush­rooms) in com­bat­ting de­pres­sion and anx­i­ety among can­cer pa­tients. Not on­ly did the psy­che­del­ic drug do the trick for most of the pa­tients, im­prov­ing a sense of well-be­ing and sat­is­fac­tion, many al­so felt it was one of the most valu­able ex­pe­ri­ences of their lives. And the treat­ment ef­fect last­ed a bull­ish­ly long six months from a sin­gle dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.